Literature DB >> 11095774

Tuberculosis and HIV Infection.

.   

Abstract

We review important new recommendations on the treatment and prophylaxis of tuberculosis in HIV-infected individuals. Large-scale studies and expert consensus panels have both concluded that shorter courses and intermittent antituberculous regimens are adequate for the treatment of dually infected individuals. Also, the substitution of rifabutin for rifampin for the treatment and prophylaxis of tuberculosis has been shown to be advantageous, providing equivalent efficacy to regimens containing rifampin, and fewer drug interactions with antiretroviral medications.

Entities:  

Year:  1999        PMID： 11095774     DOI： 10.1007/s11908-999-0017-3

Source DB:  PubMed          Journal:  Curr Infect Dis Rep        ISSN： 1523-3847            Impact factor:   3.725


  8 in total

1.  Evaluation of an intensive intermittent-induction regimen and duration of short-course treatment for human immunodeficiency virus-related pulmonary tuberculosis. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) and the AIDS Clinical Trials Group (ACTG).

Authors:  W M el-Sadr; D C Perlman; J P Matts; E T Nelson; D L Cohn; N Salomon; M Olibrice; F Medard; K D Chirgwin; D Mildvan; B E Jones; E E Telzak; O Klein; L Heifets; R Hafner
Journal:  Clin Infect Dis       Date:  1998-05       Impact factor: 9.079

Review 2.  Antimicrobial activity of rifabutin.

Authors:  C M Kunin
Journal:  Clin Infect Dis       Date:  1996-04       Impact factor: 9.079

3.  Randomised trial of isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection.

Authors:  N A Halsey; J S Coberly; J Desormeaux; P Losikoff; J Atkinson; L H Moulton; M Contave; M Johnson; H Davis; L Geiter; E Johnson; R Huebner; R Boulos; R E Chaisson
Journal:  Lancet       Date:  1998-03-14       Impact factor: 79.321

4.  Efficacy and safety of rifabutin in the treatment of patients with newly diagnosed pulmonary tuberculosis.

Authors:  M M McGregor; P Olliaro; L Wolmarans; B Mabuza; M Bredell; M K Felten; P B Fourie
Journal:  Am J Respir Crit Care Med       Date:  1996-11       Impact factor: 21.405

5.  A pilot study of antituberculosis combinations comparing rifabutin with rifampicin in the treatment of HIV-1 associated tuberculosis. A single-blind randomized evaluation in Ugandan patients with HIV-1 infection and pulmonary tuberculosis.

Authors:  S Schwander; S Rüsch-Gerdes; A Mateega; T Lutalo; S Tugume; C Kityo; R Rubaramira; P Mugyenyi; A Okwera; R Mugerwa
Journal:  Tuber Lung Dis       Date:  1995-06

6.  Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus: principles of therapy and revised recommendations. Centers for Disease Control and Prevention.

Authors: 
Journal:  MMWR Recomm Rep       Date:  1998-10-30

7.  Twice weekly tuberculosis preventive therapy in HIV infection in Zambia.

Authors:  A Mwinga; M Hosp; P Godfrey-Faussett; M Quigley; P Mwaba; B N Mugala; O Nyirenda; N Luo; J Pobee; A M Elliott; K P McAdam; J D Porter
Journal:  AIDS       Date:  1998-12-24       Impact factor: 4.177

8.  Rifabutin for the treatment of newly-diagnosed pulmonary tuberculosis: a multinational, randomized, comparative study versus Rifampicin. Rifabutin Study Group.

Authors:  L J Gonzalez-Montaner; S Natal; P Yongchaiyud; P Olliaro
Journal:  Tuber Lung Dis       Date:  1994-10
  8 in total
  1 in total

Review 1.  Drug interactions with patient-controlled analgesia.

Authors:  Jorn Lotsch; Carsten Skarke; Irmgard Tegeder; Gerd Geisslinger
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.